Androgen Receptor Signaling Inhibitors in Nonmetastatic Castration-resistant Prostate Cancer and Risk of Cardiovascular Toxicity: All That Glitters Isn’t Gold

Androgen receptor signaling inhibitors have a metastasis-free survival benefit for men with nonmetastatic castration-resistant prostate cancer. The latest updates for the PROSPER, SPARTAN, and ARAMIS trials also demonstrate an overall survival benefit. However, the cardiovascular toxicity associated with prolonged use of these agents should be taken into consideration before initiating...